We determined the anti-HBs titer in 227 children of all ages with Down syndrome (DS). Only 48.1% (95%CI: 35.1-61.3) of the DS children aged 7-10 years and 31.9% (95%CI: 22.1-43.6) of the DS children aged >10 years had a protective anti-HBs titer (≥10 IU/L). The geometric mean anti-HBs titer was significantly lower in the DS children; this suggests booster vaccination for HBV may be needed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jmv.24813 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protected or not? Hepatitis B vaccination status among healthcare workers and the level of protection post-vaccination.
Med J Armed Forces India
December 2024
Commanding Officer, 324 Field Hospital, C/o 56 APO, India.
Background: Hepatitis B virus infection is one of the major concerns in global health care. With a far-reaching health, social, economic impact, preventive strategies form the cornerstone of its management. Knowledge about vaccination status and protection rendered thereof would aid in more wholesome management among highrisk population groups like healthcare workers.
View Article and Find Full Text PDFPrevalence of hepatitis B surface antibody among previously vaccinated healthcare workers in Tashkent, Uzbekistan.
Hum Vaccin Immunother
December 2024
Central Asia Field Epidemiology Training Program, Almaty, Kazakhstan.
Healthcare workers (HCW) have high occupational risk for hepatitis B and Uzbekistan held two HCW vaccination campaigns in 2015 and 2022. Hepatitis B antibody testing (anti-HBs) after Hepatitis B (HepB) vaccination is recommended by the U.S.
View Article and Find Full Text PDFEfficacy of HBV booster dose administration in Italian medical students in relation to health determinants.
Hum Vaccin Immunother
December 2024
Department of Life, Health and Environmental Science, University of L'Aquila, L'Aquila, Italy.
We evaluated the efficacy of a booster dose of HBV in Italian medical students. We conducted a prospective observational study in students who had received a full course of anti-HBV vaccination for at least 15 y. Those with an anti-HBs titer <10 mIU/mL were offered a booster dose of the HBV vaccine and the antibody titer was reevaluated after 1 month.
View Article and Find Full Text PDFImmune response to GeneVac-B (rDNA I.P. hepatitis B vaccine) in vaccinated persons with a standard schedule in Bobo-Dioulasso, Burkina Faso.
IJID Reg
December 2024
Laboratoire de Recherche sur les Maladies Infectieuses et Parasitaire (LR-MIP), Institut de Recherche en Science de la Santé, Ouagadougou, Burkina Faso.
Objective: This study aimed to evaluate the immune response in people fully vaccinated against hepatitis B with the GeneVac-B vaccine in Burkina Faso under actual conditions of use.
Methods: This cross-sectional study included individuals fully vaccinated with GeneVac-B. For each consenting participant, sociodemographic and clinical data were collected using a structured questionnaire.
A three antigen hepatitis B vaccine induces T cells to Pres1 and Pres2 which correlate with anti HBs antibody titers: An investigation into the immunological mechanisms contributing to high anti-HBs titers.
Vaccine
January 2025
VBI Vaccines Inc, Cambridge, MA, USA. Electronic address:
Article Synopsis
- PreHevbrio® is a 3-antigen hepatitis B virus (HBV) vaccine designed to produce three types of HBV envelope proteins, leading to a more robust immune response compared to traditional single-antigen vaccines.
- The study found that the increased immunogenicity of the 3-antigen vaccine is not linked to glycosylation, but rather to its ability to trigger T cell responses specific to the PreS antigens.
- Results show that the 3-antigen vaccine generates stronger and longer-lasting antibody responses, correlating significantly with T cell activity and better antibody production.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!